MARY COHEN-COLSON: Open Payments
NPI 1831145127 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,239 in 107 payments from 9 companies in 2025. Trend: 2023 $1,950 · 2024 $1,639 · 2025 $2,239
Food & beverage: $2,123Education: $115
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $554 |
| Neurocrine BioSciences, Inc. | 18 | $509 |
| Alkermes, Inc. | 13 | $304 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $296 |
| E.R. Squibb & Sons, L.L.C. | 25 | $279 |
| Vanda Pharmaceuticals Inc. | 13 | $175 |
| Lundbeck LLC | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
Products named: INGREZZA, AUSTEDO XR, ARISTADA, CAPLYTA, COBENFY, FANAPT, REXULTI, UZEDY.
Industry payments across AL — which companies pay providers there.
